Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,